called Saxenda. “There are many people on this drug, and they will benefit by another generic version of it,” Dr. Harlan Krumholz, a cardiologist at Yale University and Yale New Haven Hospital ...

"Saxenda has the potential to help some of these ... At the moment the only drug for obesity on the market in Europe is Roche's Xenical (orlistat), a lipase inhibitor that has been available ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

as a drug with the same active ingredient known as Saxenda was released later. The generic version of Victoza, developed by UK Hikma Pharmaceuticals, is set to be launched across the United States ...

The study used the company's older GLP-1 agonist therapy Saxenda (liraglutide), which requires a daily injection, rather than its top-selling once-weekly obesity drug Wegovy (semaglutide), and ...

The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management It can be used for medicines that do not need to be authorised via ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management, Biocon Ltd said in a regulatory filing. Victoza and Saxenda are ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

The approval covers generic versions of two Novo Nordisk products: Victoza, used in the treatment of Type-2 Diabetes, and Saxenda, which is indicated for weight management. This marks a ...